Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 3/20 | 0.44 |
| ▸ | ALOX12 | P18054 | 3/20 | 0.44 |
| ▸ | EDNRB | P24530 | 1/20 | 0.40 |
| ▸ | EDNRA | P25101 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.39 |
| ▸ | ESR1 | P03372 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | KDM1A | O60341 | 2/20 | 0.36 |
| ▸ | MAOA | P21397 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | TYR | P14679 | 1/20 | 0.35 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.35 |
| ▸ | TUBB | P07437 | 1/20 | 0.35 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.35 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15312298 | 1.00 | ALOX15 (0.44) | ALOX15ALOX12EDNRBEDNRAESR2 | |
| SCHEMBL10028904 | 1.00 | ALOX15 (0.44) | ALOX15ALOX12EDNRBEDNRAESR2 | |
| SCHEMBL30362843 | 1.00 | ALOX15 (0.44) | ALOX15ALOX12EDNRBEDNRAESR2 | |
| SCHEMBL615749 | 0.96 | ALOX15 (0.47) | ALOX15ALOX12EDNRBEDNRAESR2 | |
| SCHEMBL10042959 | 0.93 | ALOX15 (0.44) | ALOX15ALOX12EDNRBEDNRAALDH1A1 | |
| Me-344 SCHEMBL30362759 | 0.92 | ESR2 (0.36) | ALOX15ALOX12ESR2ESR1PTGS1 | |
| Me-344 SCHEMBL2713213 | 0.92 | ESR2 (0.36) | ALOX15ALOX12ESR2ESR1PTGS1 | |
| Me-344 SCHEMBL30276333 | 0.92 | ESR2 (0.36) | ALOX15ALOX12ESR2ESR1PTGS1 | |
| Me-344 SCHEMBL15312098 | 0.92 | ESR2 (0.36) | ALOX15ALOX12ESR2ESR1PTGS1 | |
| Me-344 SCHEMBL29370582 | 0.92 | ESR2 (0.36) | ALOX15ALOX12ESR2ESR1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 111 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120251630-A1 | REMISSION THERAPY OF CANCER WITH ISOFLAVONOIDS | MARSHALL EDWARDS, INC. (US) | 2012-10-04 | — | — | US | claimed |
| US-20120039917-A1 | IMMUNOMODULATING ACTIVITIES | MARSHALL EDWARDS, INC. | 2012-02-16 | — | — | US | claimed |
| JP-2012500809-A | — | — | 2012-01-12 | — | — | JP | claimed |
| EP-1794141-B1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | MARSHALL EDWARDS INC (US) | 2011-11-09 | — | — | EP | claimed |
| CN-102215841-A | Immunomodulating activities | NOVOGEN RES PTY LTD | 2011-10-12 | — | — | CN | claimed |
| EP-2334296-A1 | IMMUNOMODULATING ACTIVITIES | Novogen Research Pty. Ltd. (AU) | 2011-06-22 | — | — | EP | claimed |
| US-20100173983-A1 | METHOD FOR INDUCING AUTOPHAGY | MARSHALL EDWARDS, INC. | 2010-07-08 | — | — | US | claimed |
| US-20100130598-A1 | METHODS FOR INDUCING PROGRAMMED CELL DEATH | NOVOGEN RESEARCH PTY LTD. (AU) | 2010-05-27 | — | — | US | claimed |
| WO-2010022467-A1 | IMMUNOMODULATING ACTIVITIES | NOVOGEN RESEARCH PTY LTD (AU) | 2010-03-04 | — | — | WO | claimed |
| EP-2120925-A1 | METHOD FOR INDUCING AUTOPHAGY | Novogen Research Pty. Ltd. (AU) | 2009-11-25 | — | — | EP | claimed |
| WO-2008113100-A1 | METHOD FOR INDUCING AUTOPHAGY | NOVOGEN RESEARCH PTY LTD (AU) | 2008-09-25 | — | — | WO | claimed |
| US-12414934-B2 | Combination therapies | Aardvark Therapeutics, Inc. (US) | 2025-09-16 | — | — | US | disclosed |
| US-12318364-B2 | Isoflavonoid compositions and methods for the treatment of cancer | Aardvark Therapeutics, Inc. (US) | 2025-06-03 | — | — | US | disclosed |
| WO-2024137472-A2 | COMBINATION THERAPIES | MEI PHARMA, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240165073-A1 | ISOFLAVONOID COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | Aardvark Therapeutics, Inc. | 2024-05-23 | — | — | US | disclosed |
| EP-1794141-A4 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RES PTY LTD (AU) | 2009-05-27 | — | — | EP | disclosed |
| WO-2008113100-A1 | METHOD FOR INDUCING AUTOPHAGY | NOVOGEN RESEARCH PTY LTD (AU) | 2008-09-25 | — | — | WO | disclosed |
| EP-1794141-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | Novogen Research Pty. Ltd. (AU) | 2007-06-13 | — | — | EP | disclosed |
| US-20060074127-A1 | anticancer agents; chemotherapeutic selective agents | NOVOGEN RESEARCH PTY LTD | 2006-04-06 | — | — | US | disclosed |
| WO-2006032085-A1 | SUBSTITUTED CHROMAN DERIVATIVES, MEDICAMENTS AND USE IN THERAPY | NOVOGEN RESEARCH PTY LTD (AU) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12414934-B2 | Combination therapies | PCK2, PDK1, PCK1 | ALOX15 3776/4885ALOX12 3348/4885EDNRB 2845/4885 |
| US-20120251630-A1 | REMISSION THERAPY OF CANCER WITH ISOFLAVONOIDS | CYP19A1, HSD17B11, BRCA1 | ALOX15 1669/4885ALOX12 1582/4885EDNRB 738/4885 |
| US-20120039917-A1 | IMMUNOMODULATING ACTIVITIES | CD4, NFATC1, HRH2 | ALOX15 938/4885ALOX12 588/4885EDNRB 813/4885 |
| US-20240165073-A1 | ISOFLAVONOID COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | BAX, CASP3, SI | ALOX15 1569/4885ALOX12 1537/4885EDNRB 2355/4885 |
| US-12318364-B2 | Isoflavonoid compositions and methods for the treatment of cancer | BAX, CASP3, SI | ALOX15 1569/4885ALOX12 1537/4885EDNRB 2355/4885 |
| US-20100173983-A1 | METHOD FOR INDUCING AUTOPHAGY | BECN1, SQSTM1, ATG7 | ALOX15 797/4885ALOX12 594/4885EDNRB 4070/4885 |
| US-20060074127-A1 | anticancer agents; chemotherapeutic selective agents | MCL1, TOP2A, TP53 | ALOX15 4437/4885ALOX12 4403/4885EDNRB 4307/4885 |
| US-20100130598-A1 | METHODS FOR INDUCING PROGRAMMED CELL DEATH | CASP3, BAX, BAD | ALOX15 252/4885ALOX12 211/4885EDNRB 4059/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.